UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Biomarkers immune monitoring technology primer: Immunoscore® Colon

Journal for immunotherapy of cancer, 2016-09, Vol.4 (1), p.57-57, Article 57

Hermitte, Fabienne

2016

Volltextzugriff (PDF)

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Journal of clinical oncology, 2009-11, Vol.27 (31), p.5195-5201

2009

Volltextzugriff (PDF)

Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer

Cell death & disease, 2020-04, Vol.11 (4), p.275, Article 275

2020

Volltextzugriff (PDF)

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

Journal for immunotherapy of cancer, 2020-05, Vol.8 (1), p.e000272

2020

Volltextzugriff (PDF)

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI cancer spectrum, 2020-06, Vol.4 (3), p.pkaa023-pkaa023

2020

Volltextzugriff (PDF)

Identification and validation of an ERBB2 gene expression signature in breast cancers

Oncogene, 2004-04, Vol.23 (14), p.2564-2575

2004

Volltextzugriff (PDF)

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

Annals of oncology, 2020-07, Vol.31 (7), p.921-929

2020

Volltextzugriff (PDF)

How basal are triple‐negative breast cancers?

International journal of cancer, 2008-07, Vol.123 (1), p.236-240

2008

Volltextzugriff (PDF)

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Clinical cancer research, 2021-05, Vol.27 (10), p.2755-2763

2021

Volltextzugriff (PDF)

Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy

Molecular aspects of medicine, 2019-10, Vol.69, p.123-129

2019

Volltextzugriff (PDF)

ZENON, a Novel POZ Kruppel-Like DNA Binding Protein Associated with Differentiation and/or Survival of Late Postmitotic Neurons

Molecular and Cellular Biology, 2005-03, Vol.25 (5), p.1713-1729

2005

Volltextzugriff (PDF)

Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring

Cancers, 2022-02, Vol.14 (5), p.1170

2022

Volltextzugriff (PDF)

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

Cancers, 2020-10, Vol.12 (10), p.3073

2020

Volltextzugriff (PDF)

Abstract CT010: A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced sarcoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT010-CT010

2019

Volltextzugriff (PDF)

Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.CT069-CT069

2019

Volltextzugriff (PDF)

Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4105-4105

2020

Volltextzugriff (PDF)

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.10-10

2020

Volltextzugriff (PDF)

Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14615-e14615

2017

Volltextzugriff (PDF)

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3513-3513

2019

Volltextzugriff (PDF)

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.614-614

2018

Volltextzugriff (PDF)

Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.487-487

2019

Volltextzugriff (PDF)

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3579-3579

2017

Volltextzugriff (PDF)

Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15149-e15149

2018

Volltextzugriff (PDF)

Under-Expression of LINE-1 Retrotransposons in Chronic Myeloid Leukemia Patients: Effect of Tyrosine Kinase Inhibitors

Blood, 2014-12, Vol.124 (21), p.5514-5514

2014

Volltextzugriff (PDF)

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Annals of oncology, 2017-06, Vol.28, p.iii153-iii153

2017

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Biomarkers immune monitoring technology primer: Immunoscore® Colon

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

Identification and validation of an ERBB2 gene expression signature in breast cancers

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

How basal are triple‐negative breast cancers?

Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy

ZENON, a Novel POZ Kruppel-Like DNA Binding Protein Associated with Differentiation and/or Survival of Late Postmitotic Neurons

Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring

Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer

Abstract CT010: A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced sarcoma

Abstract CT069: A Phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance)

Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response

Under-Expression of LINE-1 Retrotransposons in Chronic Myeloid Leukemia Patients: Effect of Tyrosine Kinase Inhibitors

Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance)

Suchergebnisse filtern